Shield Therapeutics upbeat as Accrufer trial initiated in Japan
(Alliance News) - Shield Therapeutics PLC on Friday reported the commencement of a phase two Accrufer trial in Japan for the treatment of pulmonary arterial hypertension. Read More
| Price | 6.65p on 18-11-2025 at 19:40:08 |
|---|---|
| Change | -0.10p -1.48% |
| Buy | 6.80p |
| Sell | 6.50p |
| Last Trade: | Buy 258,712.00 at 6.6725p |
| Day's Volume: | 1,106,570 |
| Last Close: | 6.65p |
| Open: | 6.75p |
| ISIN: | GB00BYV81293 |
| Day's Range | 6.50p - 6.65p |
| 52wk Range: | 2.20p - 9.00p |
| Market Capitalisation: | £70.61m |
| VWAP: | 6.610868p |
| Shares in Issue: | 1.06b |
Sector: Medicine and Biotech
Listed In: FTSE AIM All-Share,
Shield Thera (STX) Latest Trades |
||||
| Buy/Sell | Volume | Trade Prc | Trade Type | Trade Time |
|---|---|---|---|---|
| Buy* | 258,712 | 6.6725p | Ordinary |
16:26:39 - 18-Nov-25 |
| Buy* | 32,835 | 6.70p | Ordinary |
15:54:34 - 18-Nov-25 |
| Sell* | 2,066 | 6.55755p | Ordinary |
15:38:26 - 18-Nov-25 |
| Buy* | 14 | 6.80p | SI Trade |
14:45:38 - 18-Nov-25 |
| Buy* | 29 | 6.80p | SI Trade |
14:45:38 - 18-Nov-25 |
| Sell* | 307,900 | 6.50p | Ordinary |
14:44:53 - 18-Nov-25 |
| Buy* | 13,750 | 6.6975p | Ordinary |
14:28:25 - 18-Nov-25 |
| Sell* | 39,299 | 6.62p | Ordinary |
14:03:34 - 18-Nov-25 |
| Sell* | 79,999 | 6.50p | Uncrossing Trade |
14:00:14 - 18-Nov-25 |
| Sell* | 10,000 | 6.62p | Ordinary |
13:57:39 - 18-Nov-25 |
Shield Thera (STX) Regulatory News |
||
| Date | Source | Headline |
|---|---|---|
| 14th Nov 2025 7:03 am | RNS | Initiation of a Phase II Clinical Trial in Japan |
| 11th Nov 2025 7:00 am | RNS | ACCRUFeR Pediatric PK Results to be Presented |
| 7th Nov 2025 7:03 am | RNS | ACCRUFeR receives Authorisation by Korean Ministry |
| 23rd Oct 2025 7:00 am | RNS | Q3 2025 Trading Update |
| 14th Oct 2025 3:01 pm | RNS | Grant of Share Options to Chief Executive Officer |
| 1st Oct 2025 8:00 am | RNS | Total Voting Rights |
| 1st Oct 2025 7:02 am | RNS | Positive efficacy and tolerance in pediatric trial |
| 15th Sep 2025 7:00 am | RNS | £1.5 million placing supporting growth of ACCRUFeR |
| 4th Sep 2025 7:03 am | RNS | ACCRUFeR® assigned Priority Review in US by FDA |
| 3rd Sep 2025 2:17 pm | RNS | Interim results for the six months ended 30 Jun 25 |